Solara Active Pharma Sciences (SOLARAPP1) Stock Overview
Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SOLARAPP1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Solara Active Pharma Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹401.60 |
| 52 Week High | ₹524.90 |
| 52 Week Low | ₹214.35 |
| Beta | 1.07 |
| 1 Month Change | -2.05% |
| 3 Month Change | -14.55% |
| 1 Year Change | -12.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 87.80% |
Recent News & Updates
Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP1) Can Manage Its Debt Responsibly
Nov 12
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARAPP1) Revenues Despite 26% Price Jump
Jun 27Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP) Can Manage Its Debt Responsibly
May 23Recent updates
Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP1) Can Manage Its Debt Responsibly
Nov 12Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARAPP1) Revenues Despite 26% Price Jump
Jun 27Here's Why Solara Active Pharma Sciences (NSE:SOLARAPP) Can Manage Its Debt Responsibly
May 23Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Could Be Riskier Than It Looks
Jan 25Solara Active Pharma Sciences Limited (NSE:SOLARAPP) Soars 38% But It's A Story Of Risk Vs Reward
Sep 19We Think Solara Active Pharma Sciences (NSE:SOLARAPP) Has A Fair Chunk Of Debt
Aug 24Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARAPP) Revenues Despite 55% Price Jump
Jul 28Shareholder Returns
| SOLARAPP1 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 10.1% | 0.6% | 1.2% |
| 1Y | -12.6% | -3.0% | -2.4% |
Return vs Industry: SOLARAPP1 underperformed the Indian Pharmaceuticals industry which returned -2.2% over the past year.
Return vs Market: SOLARAPP1 underperformed the Indian Market which returned -2.3% over the past year.
Price Volatility
| SOLARAPP1 volatility | |
|---|---|
| SOLARAPP1 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.6% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: SOLARAPP1's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SOLARAPP1's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 1,775 | Sandeep Rao | www.solara.co.in |
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support.
Solara Active Pharma Sciences Limited Fundamentals Summary
| SOLARAPP1 fundamental statistics | |
|---|---|
| Market cap | ₹28.56b |
| Earnings (TTM) | ₹64.10m |
| Revenue (TTM) | ₹12.06b |
Is SOLARAPP1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOLARAPP1 income statement (TTM) | |
|---|---|
| Revenue | ₹12.06b |
| Cost of Revenue | ₹5.88b |
| Gross Profit | ₹6.18b |
| Other Expenses | ₹6.12b |
| Earnings | ₹64.10m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 51.27% |
| Net Profit Margin | 0.53% |
| Debt/Equity Ratio | 49.6% |
How did SOLARAPP1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:18 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Solara Active Pharma Sciences Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Alankar Garude | Macquarie Research |